H105A peptide eye drops are not an FDA-approved prescription treatment and are not broadly available to buy for patient use. Current evidence is preclinical: mouse models of retinitis pigmentosa-like disease and human retinal tissue models. NIH has described the technology as available for licensing and co-development, with human trials still needed 1, 2.
Wondering if peptide therapy is right for you? Take the 3-min clinical quiz.
See if you qualify →Can you buy H105A peptide eye drops right now?
H105A peptide is not an approved drug, and there is no established FDA-approved dose or consumer eye-drop product for patients. Online pages that make H105A sound ready for treatment should be read with caution because the published evidence is still preclinical 1, 2.
Why online “buy H105A” claims need caution
A research chemical listing, patent notice, or supplier page is not the same as a prescription medication. We use this same distinction in our broader guidance on peptide group buys: the safety question is not just “can I find it online?” but whether there is human evidence, licensed clinical oversight, and a legitimate pharmacy or trial pathway.
For H105A, the current public record points to laboratory and animal development, not routine patient care. The Federal Register notice describes pigment epithelium-derived factor peptide technology as available for licensing and co-development and lists its development stage as preclinical in vivo validation 2.
Research use, licensing, and patient treatment are different
Licensing means a technology owner may work with a company or research partner to develop the invention. It does not mean a patient can safely buy it, a pharmacy can routinely prepare it for eye disease, or a clinician can rely on proven human outcomes. Before a new eye drug reaches patients, it usually needs toxicology work, an investigational new drug process, and human trials 3.
What is H105A peptide?
H105A peptide is a small peptide derived from pigment epithelium-derived factor, or PEDF. More precisely, it is described as PEDF 17-mer[H105A], a 17-amino-acid PEDF-region peptide with a histidine-to-alanine change at position 105 that was designed to bind more strongly to the PEDF receptor 1, 4.
How H105A relates to pigment epithelium-derived factor, or PEDF
PEDF is a protein found in the eye and other tissues. Researchers study it because it appears to help protect retinal cells under stress. H105A is not full-length PEDF; it is a smaller PEDF-derived fragment designed to keep some retinal-protective signaling while being easier to formulate as an eye-drop candidate 1.
How H105A differs from the 17-mer PEDF peptide
The original 17-mer PEDF peptide contains 17 amino acids from an active region of PEDF. H105A is a variant of that 17-mer peptide. In the published study and AAO summary, the H105A version was reported to bind more strongly to the PEDF receptor than the original 17-mer peptide 1, 4.
Why researchers are studying a gene-agnostic retinal approach
Inherited retinal diseases can involve many different genes. A mutation-independent, or gene-agnostic, approach aims to support stressed photoreceptors regardless of the specific mutation. That idea is still being tested; it should not be read as proof that H105A works in people with retinitis pigmentosa, Leber congenital amaurosis, cone-rod dystrophy, Stargardt-like maculopathy, dry age-related macular degeneration, or any other retinal disease 2, 5.
What eye diseases is H105A being studied for?
H105A peptide eye drops are being studied mainly for retinal degeneration biology, with retinitis pigmentosa-like mouse models as a key published test system. NIH’s licensing notice also discusses inherited retinal diseases and age-related macular degeneration as possible development areas, but that is not the same as approval or proven treatment 1, 2.
Retinitis pigmentosa
Retinitis pigmentosa is a group of inherited retinal diseases in which photoreceptors break down over time, often causing night-vision problems and gradual vision loss. It is genetically diverse, which is one reason researchers are interested in retinal-support approaches that might not depend on one gene target 5, 6.
Inherited retinal diseases
The NIH notice describes the PEDF peptide technology for inherited retinal diseases and includes both an eye-drop formulation and an AAV2-based delivery system concept. AAV2 is a viral-vector platform used in some gene-delivery research. For H105A, this is a development concept, not a patient-ready option 2.
Dry age-related macular degeneration and other retinal degeneration hypotheses
Dry age-related macular degeneration, or dry AMD, is a separate retinal condition that affects the macula, the part of the retina used for central vision. The NIH notice and secondary reports mention AMD as an area of interest, but H105A has not been shown in human trials to improve dry AMD outcomes 2, 7.
Why preclinical signals do not prove patient benefit
Animal and tissue models help scientists decide whether a treatment deserves more study. They cannot prove that a medicine will improve vision, slow vision loss, or be safe in humans. Eye treatments also need careful safety testing because the retina is delicate and vision changes can be permanent 3.
What does the H105A evidence actually show?
The best public evidence for H105A peptide is preclinical. In a mouse model of retinitis pigmentosa-like disease, once-daily eye drops started 2 weeks after birth were reported to preserve photoreceptors and retinal light responses compared with placebo, but no human efficacy, dosing, or long-term safety has been established 1, 4.
Mouse retinitis pigmentosa model findings
In the animal study summarized by the American Academy of Ophthalmology, researchers used specially bred mice whose photoreceptors die early in life. The AAO summary reported that treated mice had up to 75% photoreceptor preservation and stronger light responses compared with placebo-treated animals 4. Individual human results cannot be inferred from this animal finding.
Human retinal tissue model findings
Researchers also tested H105A in human retinal tissue models exposed to oxidative stress, such as cigarette-smoke extract in the AAO summary. Treated tissue models reportedly stayed viable longer than untreated models, but this is still a tissue-model result, not a human clinical trial 1, 4.
What the study did not show
The study did not establish a proven human dose, treatment schedule, vision outcome, or long-term safety profile. It also did not show that patients can safely use research-grade H105A products bought online. Those are exactly the kinds of gaps that IND-enabling studies and first-in-human trials are meant to address 3.
| Question | What we know | What we do not know yet |
|---|---|---|
| What is the compound? | A PEDF-derived investigational retinal peptide called PEDF 17-mer[H105A]. | No established brand name or generic INN is assigned. |
| What form was studied? | Eye-drop formulations in preclinical models; NIH also describes an AAV2 delivery concept. | No approved consumer eye-drop product exists. |
| What evidence exists? | Mouse retinal degeneration models and human retinal tissue models. | No completed human trials proving benefit, dosing, or long-term safety. |
| Can patients buy it for treatment? | Not as an FDA-approved prescription treatment. | Online sales claims should not be treated as evidence of safety or effectiveness. |
Is H105A FDA approved or in human clinical use?
H105A peptide eye drops are not FDA-approved for any eye disease. NIH’s public notice lists the technology at a preclinical in vivo validation stage, which means it is before routine human clinical use 2.
Preclinical development status
Preclinical development means researchers are still studying the treatment in laboratory systems and animals. This stage can help answer early questions about mechanism, delivery, and toxicity. It does not answer whether a treatment improves human vision or how it should be used in patients 3.
NIH licensing and co-development notice
The Federal Register notice describes “Pigment Epithelium-Derived Factor Peptides and Their Use for Treating Retinal Degeneration” as a government-owned invention available for license and co-development. It names possible applications, including inherited retinal diseases and age-related macular degeneration, while still identifying the development stage as preclinical 2.
What IND-enabling studies and first-in-human trials mean
IND-enabling studies are the safety and manufacturing studies used to support an investigational new drug application before human testing. First-in-human trials are early studies that usually focus on safety, tolerability, and basic dosing information. These steps are important because a promising retina result in animals may fail, need a different dose, or show safety issues in people 3, 8.
How does H105A compare with other retinal treatment options?
H105A is an investigational peptide, while some retinal diseases have approved or guideline-based options that depend on diagnosis, genetics, and disease stage. The key difference is that H105A has 0 completed human efficacy trials in routine care, while approved treatments have gone through formal FDA review for specific uses 3, 9.
Approved treatments versus investigational peptides
For some inherited retinal diseases, approved gene therapies may apply only to people with specific confirmed gene variants. For some forms of macular degeneration, approved injected medicines or other eye-care strategies may be used depending on whether the disease is wet AMD, dry AMD, or geographic atrophy. A retina specialist can help sort out which category fits your eye findings 7, 9.
Gene-specific therapies versus mutation-independent approaches
Gene-specific therapy targets a known genetic cause. A mutation-independent retinal-support approach, like the H105A research idea, aims to help stressed photoreceptors without correcting one specific mutation. That concept is scientifically interesting, but it remains unproven for patients until human trials show safety and meaningful outcomes 1, 2.
Why a retina specialist should guide care
Symptoms like new floaters, flashes, sudden blind spots, curtain-like vision loss, or rapid vision change can signal urgent eye problems. A retina specialist can perform imaging, visual-field testing, genetic testing when appropriate, and treatment planning. Buying an investigational peptide online can delay the care that protects remaining vision.
Can you buy H105A peptide through Chia?
No. Chia does not offer H105A, PEDF peptide eye drops, or retinal disease treatment, and we do not list it as part of our licensed-provider catalog. Our available treatments require a 100% online licensed-provider review, clinical eligibility, and dispensing through state-licensed 503A pharmacies when prescribed.
Chia does not offer H105A, PEDF peptide eye drops, or retinal disease treatment
Chia’s current catalog includes treatments such as semaglutide injection, tirzepatide tablets and injection, NAD+ injection and nasal spray, glutathione injection and nasal spray, Sermorelin, GHK-Cu cream, and other listed therapies. H105A is not in that catalog, and we will not imply access to a treatment we do not provide.
Why Chia only lists treatments available through its licensed-provider model
At Chia, a treatment starts with a health questionnaire and review by a licensed US provider. A prescription is never guaranteed. When clinically appropriate, medications are compounded in the US by state-licensed 503A pharmacies and shipped to the patient’s door. Compounded medications are not FDA-approved.
That licensed pathway is very different from buying a vial or eye-drop product from an unverified online seller. We explain the same safety concern in our articles on BPC-157 buying risks, TB-500 online access, and Klotho peptide availability: access without medical review can create avoidable risk, especially for investigational compounds.
When to seek urgent or specialty eye care instead of buying peptides online
If you have sudden vision loss, eye pain, flashes, new floaters, a shadow or curtain in vision, or a fast change in central vision, seek urgent eye care or emergency care. If you have gradual night-vision loss, family history of inherited retinal disease, or known retinal degeneration, a retina specialist can guide genetic testing, monitoring, approved options, and clinical-trial searches.
What should patients do instead of buying H105A online?
Instead of buying H105A peptide online, the safest next step is a medical eye exam and, when needed, a retina-specialist visit. For investigational options, use legitimate clinical-trial channels rather than research-chemical sellers; a real study will have oversight, eligibility criteria, informed consent, and safety monitoring 8.
- 1Book an eye exam for new or worsening symptoms. Sudden or severe symptoms need urgent evaluation.
- 2Ask whether your findings suggest retinitis pigmentosa, inherited retinal disease, dry AMD, wet AMD, or another diagnosis.
- 3If inherited retinal disease is possible, ask whether genetic testing is appropriate.
- 4Ask your retina specialist about approved treatments, low-vision support, and clinical trials.
- 5Search ClinicalTrials.gov or an academic retina center for legitimate studies, not social-media sellers or peptide marketplaces.
If your broader goal is longevity, metabolic health, or a treatment Chia actually offers, our providers can review eligibility through our online care model. But for H105A, PEDF eye drops, and retinal disease care, we recommend specialty eye care rather than an online peptide purchase.
No peptide is broadly approved simply to “improve eyesight.” H105A is an investigational PEDF-derived retinal peptide studied in animal and tissue models, not a proven human vision treatment. Eye symptoms should be evaluated by an eye-care professional.
There is no peptide with proven broad effectiveness for treating macular degeneration. Macular degeneration treatment depends on the type and stage of disease. A retina specialist can explain approved options and whether any clinical trials are relevant.
H105A and related PEDF peptides are being studied for retinitis pigmentosa-like retinal degeneration, but they are not FDA-approved treatments. Current evidence is preclinical, so patients should not buy them online for self-treatment.
PEDF peptide eye drops are being researched as a possible way to support stressed photoreceptors in retinal degeneration models. They are not approved for patient use for retinitis pigmentosa, macular degeneration, or other eye diseases.
No. PEDF is the full pigment epithelium-derived factor protein. H105A is a smaller PEDF-derived 17-amino-acid peptide variant, also called PEDF 17-mer[H105A], with a specific amino-acid substitution.
Human safety has not been established. Published H105A work is preclinical, so it cannot define human dosing, long-term risks, or whether the eye drops help vision in people.
H105A is investigational and not a routine FDA-approved prescription treatment. Chia does not offer H105A, PEDF peptide eye drops, or retinal disease treatment. Do not assume an online seller or compounding claim means a product is appropriate or safe for eye use.
Search ClinicalTrials.gov and ask an academic retina center or retina specialist. A legitimate clinical trial should list the sponsor, eligibility rules, study site, oversight, and informed-consent process.
References
- 1.Becerra SP and colleagues. H105A peptide eye drops promote photoreceptor survival in models of retinal degeneration. Communications Medicine. 2025.
- 2.National Institutes of Health. Government-Owned Invention Available for License: Pigment Epithelium-Derived Factor Peptides and Their Use for Treating Retinal Degeneration. Federal Register. 2026.
- 3.U.S. Food and Drug Administration. The FDA’s Drug Review Process: Ensuring Drugs Are Safe and Effective. FDA. 2024.
- 4.American Academy of Ophthalmology. Eye Drops Slow Retinal Disease in Animal Study. EyeNet Magazine. 2025.
- 5.National Eye Institute. Retinitis Pigmentosa. National Institutes of Health. 2023.
- 6.MedlinePlus Genetics. Retinitis pigmentosa. National Library of Medicine. 2024.
- 7.National Eye Institute. Age-Related Macular Degeneration. National Institutes of Health. 2024.
- 8.National Library of Medicine. Learn About Clinical Studies. ClinicalTrials.gov. 2024.
- 9.U.S. Food and Drug Administration. FDA approves novel gene therapy to treat patients with a rare form of inherited vision loss. FDA. 2017.
About this article
Chia Health Editorial Team — Evidence-reviewed health education
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
AI tools may assist with research and drafting. Chia's editorial team reviews source use, clarity, treatment information, and safety framing before publication. A clinician is named only after explicit sign-off. Read our editorial standards.
Get a personalized plan
See if peptide therapy is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
